Conagra Brands's Next Earnings Report on Sep. 30 2026 Could Send the Stock Soaring. Here's Why.

Conagra is expected to report fiscal Q1 2027 net sales of $2.59 billion, down less than 2% year over year, and adjusted EPS of $0.28, down 28%. The company’s fundamentals remain under pressure: annual sales have declined in every year since fiscal 2023, fiscal 2026 included a $1.9 billion GAAP loss driven largely by more than $2.9 billion of impairment charges, and adjusted profit fell to $823 million from over $1.1 billion. Conagra also halved its quarterly dividend to just under $0.18 per share, while investors await evidence that new CEO John Brase can shift the legacy packaged-food portfolio toward changing consumer preferences.

Analysis

CAG’s near-term setup is asymmetric only if the company can demonstrate that volume/mix erosion has stabilized; a mechanical EPS beat driven by timing, lower incentives, or cost controls should not sustain a rerating. With the dividend reset removing the income-holder base, the equity is likely to trade primarily on evidence that price elasticity, frozen-food volumes, and promotional intensity are improving—not on adjusted EPS alone. The key read-through is whether gross-margin preservation is being bought through market-share losses, which would defer rather than solve the earnings problem.

The more consequential catalyst over the next 1-3 months is new CEO capital-allocation and portfolio commentary. A credible plan to divest low-growth brands, reduce leverage, and redirect marketing/innovation toward higher-velocity categories could narrow CAG’s valuation discount to packaged-food peers such as GIS, KHC, and CPB; absent this, impairment risk remains a signal that acquired-brand cash flows are below prior underwriting. Retailer inventory normalization or a step-up in promotional spending would pressure FY27 guidance quickly, particularly if commodity deflation is competed away rather than retained.

Contrarianly, expectations appear low enough for a one-quarter relief rally, but that is not equivalent to a durable long thesis. The market may underappreciate the balance-sheet benefit from lower cash distributions, yet management must prove that retained cash converts into debt reduction or organic growth rather than merely cushioning declining operating profit. A sustained recovery requires sequential volume improvement and stable gross margin for at least two reporting periods, making this principally a watch-list turnaround rather than a pre-earnings core position.

Key Decisions for Investors

• Avoid establishing a directional CAG position ahead of earnings unless channel data show improving frozen/snack unit volumes; the likely upside from a modest beat is vulnerable to a rapid reversal without FY27 guidance support.
• For event-driven exposure, consider a small post-results long CAG only if organic volume is flat-to-up year over year, full-year adjusted EPS guidance is maintained or raised, and management quantifies debt reduction or portfolio actions. Target a 10-15% relief move over 1-3 months; exit if volume remains negative or gross margin contracts sequentially.
• Prefer a relative-value expression rather than outright defensive-food beta: long GIS or CPB versus short CAG over 3-6 months if CAG confirms continued share loss or lowers guidance. The thesis is that larger peers’ brand investment and category exposure should command steadier multiples while CAG absorbs restructuring and execution risk.
• Set an alert around any further impairment, covenant/leverage commentary, or another dividend-policy change. These would challenge the cash-flow recovery narrative and could justify a tactical CAG short, particularly if consensus earnings estimates have not yet reset.